Reimbursement for HPV Vaccine Cost in the Private Sector: A Comparison Across Specialties

Authors

Yenan Zhu
Yueh-Yun Lin
Ruosha Li
Cara He
David R Lairson
Ashish A Deshmukh
Kalyani Sonawane

Language

English

Publication Date

1-1-2023

Journal

Annals of Family Medicine

DOI

10.1370/afm.2990

PMID

37487718

PMCID

PMC10365861

PubMedCentral® Posted Date

July 2023

PubMedCentral® Full Text Version

Post-print

Abstract

The human papillomavirus (HPV) vaccine is the most expensive of all routinely recommended pediatric vaccines. Adequate cost reimbursement by 3rd-party payers is a critical enabling factor for clinicians to continue offering vaccines. This study found that net returns from HPV vaccine cost reimbursements are lowest for family physicians ($0.34/dose) and highest for pediatricians ($5.08/dose). Furthermore, a $1 increment in return was associated with an increase in HPV vaccine doses administered (highest for family physicians; 0.08% per dollar). Reimbursement for HPV vaccine costs by private payers is adequate; however, return margins are small for non-pediatric specialties.

Keywords

Humans, Child, Papillomavirus Vaccines, Private Sector, Physicians, Family, Medicine, Vaccination

Recommended Citation

Zhu, Yenan; Lin, Yueh-Yun; Li, Ruosha; et al., "Reimbursement for HPV Vaccine Cost in the Private Sector: A Comparison Across Specialties" (2023). Faculty, Staff and Student Publications. 397.
https://digitalcommons.library.tmc.edu/uthsph_docs/397